COMMUNIQUÉS West-GlobeNewswire

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference
27/11/2024
CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed [...]
Radiopharm Achieves Nasdaq Listing of American Depositary Shares
27/11/2024
Trading under ticker symbol RADX Complements existing US shareholders (currently holding 21% of Radiopharm) No associated capital raising Modest admin & financial compliance overheads SYDNEY, Nov. 27, 2024 (GLOBE [...]
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
27/11/2024
The reputable scientific journal, The Lancet Regional Health – Europe , has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, [...]
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
27/11/2024
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
27/11/2024
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the [...]
Kronos Bio Announces CEO Transition and Reduction in Force
27/11/2024
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, [...]
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
27/11/2024
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
27/11/2024
TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing [...]
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
27/11/2024
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah [...]
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
27/11/2024
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences: Evercore ISI HealthCONx [...]
Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
27/11/2024
TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Krystal Biotech to Present at Upcoming Investor Conferences
27/11/2024
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer [...]
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
27/11/2024
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB Phase 2b clinical [...]
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
27/11/2024
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered [...]
WW International, Inc. Announces CFO Transition
27/11/2024
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced the appointment of Felicia DellaFortuna as Chief Financial Officer, effective [...]
EDAP to Participate in the Piper Sandler 36th Annual Healthcare Conference
27/11/2024
LYON, France, November 27, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer of EDAP TMS, is scheduled to participate in a [...]
AdCare Rhode Island Launches Empowering Community Series to Support Families Confronting Addiction
26/11/2024
NORTH KINGSTOWN, R.I., Nov. 26, 2024 (GLOBE NEWSWIRE) -- AdCare Rhode Island , a leading addiction treatment provider, is launching a transformative community series aimed at empowering families grappling with the [...]
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Vyloy® (zolbetuximab-clzb)
26/11/2024
LOUISVILLE, Ky., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Astellas for Vyloy ® (zolbetuximab-clzb), approved [...]
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
26/11/2024
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today [...]

Pages